| Document |
Document Title |
|
WO/2012/098241A2 |
An optic fibre sensor comprising an optic fibre (9) and a molecularly imprinted polymer (MIP) receptor (10) formed directly on said fibre (9), wherein: said polymer includes a fluorophore that fluoresces when exposed to a source of light...
|
|
WO/2012/097857A1 |
The invention relates to chromen-4-one derivatives of formula (I), to the use thereof as self-tanning substances or for increasing melanin synthesis, improving melanin transport and/or improving the distribution of melanin in suprabasal ...
|
|
WO/2012/095707A1 |
The present invention relates to a novel process for the synthesis of the Nebivolol product depicted in Scheme 1, comprised of a reduced number of high-yield steps, and characterized by the enzymatic resolution of the chroman ester precu...
|
|
WO/2007/079840A9 |
The invention relates to benzochromene derivatives of formula (I), in which the various parameters are defined as cited in the text. The invention also relates to liquid crystal media containing said compounds, to the use of the media in...
|
|
WO/2012/091471A2 |
The present invention relates to a compound and to an organic electronic element using same, and to a terminal comprising the organic electronic element.
|
|
WO/2012/089051A1 |
The present invention provides a kind of benzopyrone compounds having a structure of formula (I) and the pharmaceutically acceptable salts or prodrugs thereof, and the pharmaceutical compositions containing such compounds, which can be u...
|
|
WO/2012/092288A2 |
Provided herein are novel crystalline forms of Compound 1. Also provided herein are compositions and methods of uses for the crystalline forms of Compound 1.
|
|
WO/2012/082236A1 |
The present invention provides a compound represented by the Formula (I): Wherein substituents R16, R17 and R17' are each independently selected from an electron withdrawing group having a Hammett op value of from 0.05 to 0.85, provided ...
|
|
WO/2012/079532A1 |
Disclosed are dicoumarol-like compounds represented by the general formula I, wherein the substituents are as defined in the specification. Also disclosed are the preparation method of the dicoumarol-like compounds and the use of the com...
|
|
WO/2012/082999A1 |
Described herein are compounds (III) comprising an indeno[2',3', 3, 4] naptho [1,2-b] pyran structure. Such compounds may be useful for their photochromic properties, and be use in certain photochromic compositions. Such compositions may...
|
|
WO/2012/082513A1 |
The present invention relates to lactone compounds represented by following Formulas I and II, and methods of making such lactone compounds. Formula (I): and formula (II). The present invention also relates to methods of making other mat...
|
|
WO/2012/082381A1 |
The present invention relates to compounds represented by the following Formulas (I) and (II). Ring-A of Formulas I and II can be, for example, an aryl group, and Q' and Q''' can each be independently selected from groups, such as, halog...
|
|
WO/2012/079938A1 |
The invention relates to compounds of formula (I): The invention likewise relates to a cosmetic method for depigmenting, lightening and/or whitening keratin materials, more particularly the skin, that utilizes these compounds
|
|
WO/2012/082506A1 |
Described herein are compounds generally comprising an indeno[2',3':3,4]naptho[1,2-b] pyran structure. Such compounds may be useful for their photochromic properties, and be used in certain photochromic compositions. Such compositions ma...
|
|
WO/2012/082837A1 |
The present invention relates to a method of making indeno-fused naphthol materials, that involves, with some embodiments, forming an indanone acid intermediate, which can be represented by the following general Formula V, [Formula V] Wi...
|
|
WO/2012/082299A1 |
Described herein are compounds generally comprising an indeno[2',3':3,4]naptho[1,2-b] pyran structure. Such compounds may be useful for their photochromic properties, and be used in certain photochromic compositions. Such compositions ma...
|
|
WO/2012/082383A1 |
The present invention relates to compounds represented by the following Formula (I). Ring-A of the Formula (I) can be, for example an aryl group, and L1 is a chiral or achiral lengthening group. The compound represented by Formula (I) ca...
|
|
WO/2012/075849A1 |
Disclosed is a genistein derivative, 4',5-dihydroxy-7-[4-(N, N-diethylamino) butoxy] isoflavones, and a preparation method and application thereof. The 4',5-dihydroxy-7-[4-(N, N-diethylamino) butoxy] isoflavones is acquired via chemical ...
|
|
WO/2012/072489A1 |
The invention relates to novel alpha,beta-unsaturated imines, to a method for producing same, to the use thereof for combating animal pests, including anthropods and in particular insects, and to the use thereof in vector control.
|
|
WO/2011/156479A9 |
Compounds and methods related to the activation of the TrkB receptor are provided. The methods include administering a 7,8-dihydroxyflavone derivative with modified flavone or heterocyclic ring to a subject in need thereof. Methods and c...
|
|
WO/2012/070024A1 |
Compositions for the treatment of cancer comprising coumarin and thiocoumarin derivatives of Formulas I- XII are disclosed. Said derivatives preferentially inhibit carbonic anhydrase IX and XII (which are associated with hypoxic and meta...
|
|
WO/2012/061958A1 |
The present invention provides flavone derivatives, preparative method of the derivatives and use thereof as medicaments for treating diabetes. The structure of the derivatives is presented by formula 1: In the structure, R1 and R2, whic...
|
|
WO/2012/064229A1 |
The invention relates to the chemical and pharmaceutical industry. The essence of the invention is that Siberian or Dahurian larch wood is stripped of bark, chopped up and dried at 40-50°C to a residual humidity of 15-25%. The dried woo...
|
|
WO/2012/062901A2 |
Compounds of formula (IIc); wherein X3 and X4 independently from each other are N or CR8 wherein R8 may be same or different; Y1, Y2, Y3 and Y4 independently from each other are N or CR9 wherein R9 may be same or different and wherein up...
|
|
WO/2012/062905A2 |
Compounds according to the general formula (I) wherein X1, X2, X3 and X4 independently from each other are N or CR8 wherein R8 may be same or different, and wherein up to 3 of the group X1, X2, X3 and X4 may be N; A is a 5- or 6-membered...
|
|
WO/2012/065139A2 |
The invention provides methods and pharmaceutical compositions for treating cancer or promoting apoptosis of cancer cells, or reducing the resistance of cancer cells to chemotherapy or apoptosis-promoting therapies by contacting the canc...
|
|
WO/2012/060234A1 |
An organic light-emitting device that realizes high-emission efficiency and low-driving voltage is provided. The organic light-emitting device contains a xanthone compound represented by general formula [1].
|
|
WO/2012/059512A1 |
The invention relates to a method for obtaining and purifying phytosterols and/or tocopherols from distillation residue from a transesterification of vegetable oils, in particular from the vegetable oil-based fatty acid methyl ester prod...
|
|
WO/2012/053408A1 |
The anti-Leishmania compound represented by formula (1).
|
|
WO/2012/048447A1 |
Processes for preparing and purifying lubiprostone are disclosed. Intermediates and preparation thereof are also disclosed.
|
|
WO/2012/050147A1 |
This process is characterized by reacting a salicylaldehyde derivative with an orthoacetic acid ester in the presence of a base, has advantageous features including the features (1) to (5) mentioned below, and is therefore useful: (1) ra...
|
|
WO/2012/049460A1 |
The present invention provides compounds of the formula Formula I or a salt thereof: and the uses of such compounds for the treatment of a disease or disorder involving oxidative damage, for preventing UV damage to the skin of a mammal a...
|
|
WO/2012/042078A1 |
The invention relates to chromene derivatives having formula (I), the significance of the various substituents being provided in the description. These compounds can be used as inhibitors of the TCR-Nkc interaction in T-lymphocytes.
|
|
WO/2012/039499A1 |
The probe of the present invention is for monitoring glutathione-S-transferase and/or a thiolic substance, and contains a compound bonded to any protector group represented by general formulas (1) to (3). (The definitions of the function...
|
|
WO/2012/038417A1 |
The present invention relates to a compound having the following formula (I), wherein : - R1 and R2 are alkyl groups having from 1 to 12 carbon atoms; - X1 is NH or O;- R3, R4, R5 and R6 are in particular H; - X2 is in particular -CH2-; ...
|
|
WO/2012/034519A1 |
A tannin extract of Sanguisorba officinalis L. contains tannin in a range of 35%-100% (w/w), wherein the content of total saponin is less than 10% (w/w), and the content of sanguisorbin I is less than 5% (w/w). The extract can protect bo...
|
|
WO/2012/036233A1 |
Provided is a novel compound which has MCH R1 receptor antagonistic activity and is represented by formula (I), a pharmaceutically acceptable salt thereof, or a solvate of the same. (In the formula, the portion AA represented by formula ...
|
|
WO/2012/036180A1 |
Provided is a novel compound having excellent anticancer activity and metastasis inhibition activity. An α-mangosteen diester represented by general formula (1): (in the formula, R1 represents the residue after a hydroxyl group is remov...
|
|
WO/2012/031993A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, ester or stereoisomer thereof, wherein R1 to R3 and X have the significances given herein. The present invention is also directed to processe...
|
|
WO/2012/031573A1 |
Provided is a compound as shown in general formula (I), wherein the definitions for the various substituents are as stated in the specification. Also provided are a method for preparing the compound, use of the compound in the preparatio...
|
|
WO/2012/027266A2 |
The present invention relates to methods of detecting, in a sample, embryonic stem cells, induced pluripotent stem cells, and/or cells undergoing reprogramming to produce induced pluripotent stem cells. These methods include providing a ...
|
|
WO/2012/025657A1 |
The invention relates to the use of a microorganism of the genus Brevibacterium for the biological degradation of ochratoxin A, in which the microorganism is preferably Brevibacterium casei, Brevibacterium linens, Brevibacterium iodinum ...
|
|
WO/2012/019428A1 |
Benzohydrol derivatives of formula (I), a preparation method, pharmaceutical compositions and pharmaceutical use thereof are disclosed in the invention. The derivatives can be used as rennin inhibitors to prepare the drugs for the treatm...
|
|
WO/2012/017454A1 |
The present invention relates to certain coumarin/chalcone compounds or a pharmaceutically acceptable salt thereof. The present invention particularly relates to the coumarin/chalcone compounds as anticancer agents useful for the treatme...
|
|
WO/2012/017166A2 |
or an addition salt thereof with pharmaceutically acceptable acids, for use thereof in a method for treatment of a pathological condition linked to an excessive effect of TNF-alpha and for use thereof in a method for treatment of the hum...
|
|
WO/2012/015914A2 |
Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or no...
|
|
WO/2012/004390A1 |
The invention relates to compound of generic formula (I) in which: R1 and R2 represent: OH, a hydrogen atom, a C1-C6 alkyl radical a C1-C6 alkoxy radical, a halogen, or OCOR3; R3 represents: a C1-C24 alkyl radical a C12-C24 alkenyl radic...
|
|
WO/2012/006178A1 |
The invention relates to salvinorin compositions and uses thereof. Specifically, the invention relates to administering a salvinorin compound to produce vasodilatory effect and organ protective effect from hypoxia/ischemia and reperfusio...
|
|
WO/2012/003497A1 |
The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), interme...
|
|
WO/2012/000608A2 |
The present invention relates to novel beta-aminoaldehyde derivatives of the formulae (I), (II) and (III), in which the substituents R1 to R5 and A have the meaning given in the description, to a novel process for their preparation, to i...
|
